Amgen [AMGN] vs Eli Lilly and [LLY] Detailed Stock Comparison
Amgen
NASDAQ
Loading...
Eli Lilly and
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Amgen wins in 10 metrics, Eli Lilly and wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Amgen | Eli Lilly and | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 27.04 | 62.03 | Amgen |
| Price-to-Book Ratio | 25.72 | 45.83 | Amgen |
| Debt-to-Equity Ratio | 924.46 | 243.61 | Eli Lilly and |
| PEG Ratio | 14.36 | 33.64 | Amgen |
| EV/EBITDA | 13.24 | 31.81 | Amgen |
| Profit Margin (TTM) | 17.39% | 22.67% | Eli Lilly and |
| Operating Margin (TTM) | 28.73% | 42.49% | Eli Lilly and |
| EBITDA Margin (TTM) | 28.73% | 42.49% | Eli Lilly and |
| Return on Equity | 105.67% | 77.28% | Amgen |
| Return on Assets (TTM) | 7.04% | 16.45% | Eli Lilly and |
| Free Cash Flow (TTM) | $10.39B | $414.30M | Amgen |
| Dividend Yield | 3.20% | 0.52% | Amgen |
| 1-Year Return | -11.11% | -5.24% | Eli Lilly and |
| Price-to-Sales Ratio (TTM) | 4.68 | 13.97 | Amgen |
| Enterprise Value | $208.21B | $699.85B | Eli Lilly and |
| EV/Revenue Ratio | 6.10 | 14.28 | Amgen |
| Gross Profit Margin (TTM) | 63.58% | 82.53% | Eli Lilly and |
| Revenue per Share (TTM) | $63 | $54 | Amgen |
| Earnings per Share (Diluted) | $10.98 | $12.29 | Eli Lilly and |
| Beta (Stock Volatility) | 0.48 | 0.40 | Eli Lilly and |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Amgen vs Eli Lilly and Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Amgen | 0.60% | -3.16% | 2.19% | 4.62% | 2.77% | 14.50% |
| Eli Lilly and | 3.01% | -6.20% | -1.75% | -4.00% | -5.94% | -2.02% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Amgen | -11.11% | 20.56% | 23.35% | 72.29% | 430.71% | 262.54% |
| Eli Lilly and | -5.24% | 153.00% | 398.48% | 826.62% | 1,967.62% | 1,326.25% |
Performance & Financial Health Analysis: Amgen vs Eli Lilly and
| Metric | AMGN | LLY |
|---|---|---|
| Market Information | ||
| Market Cap | $159.63B | $684.37B |
| Market Cap Category | Large cap | Mega cap |
| 10 Day Avg. Volume | 1,887,960 | 3,814,363 |
| 90 Day Avg. Volume | 2,390,963 | 3,413,861 |
| Last Close | $296.88 | $762.33 |
| 52 Week Range | $253.30 - $340.89 | $677.09 - $972.53 |
| % from 52W High | -12.91% | -21.61% |
| All-Time High | $346.85 (Jul 22, 2024) | $972.53 (Aug 19, 2024) |
| % from All-Time High | -14.41% | -21.61% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.09% | 0.45% |
| Quarterly Earnings Growth | 0.09% | 0.23% |
| Financial Health | ||
| Profit Margin (TTM) | 0.17% | 0.23% |
| Operating Margin (TTM) | 0.29% | 0.42% |
| Return on Equity (TTM) | 1.06% | 0.77% |
| Debt to Equity (MRQ) | 924.46 | 243.61 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $11.54 | $16.64 |
| Cash per Share (MRQ) | $16.38 | $3.59 |
| Operating Cash Flow (TTM) | $12.19B | $9.32B |
| Levered Free Cash Flow (TTM) | $13.09B | $-1,821,975,040 |
| Dividends | ||
| Last 12-Month Dividend Yield | 3.20% | 0.52% |
| Last 12-Month Dividend | $9.26 | $4.10 |
Valuation & Enterprise Metrics Analysis: Amgen vs Eli Lilly and
| Metric | AMGN | LLY |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 27.04 | 62.03 |
| Forward P/E | 14.36 | 33.64 |
| PEG Ratio | 14.36 | 33.64 |
| Price to Sales (TTM) | 4.68 | 13.97 |
| Price to Book (MRQ) | 25.72 | 45.83 |
| Market Capitalization | ||
| Market Capitalization | $159.63B | $684.37B |
| Enterprise Value | $208.21B | $699.85B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 6.10 | 14.28 |
| Enterprise to EBITDA | 13.24 | 31.81 |
| Risk & Other Metrics | ||
| Beta | 0.48 | 0.40 |
| Book Value per Share (MRQ) | $11.54 | $16.64 |
Financial Statements Comparison: Amgen vs Eli Lilly and
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | AMGN | LLY |
|---|---|---|
| Revenue/Sales | $8.15B | $12.73B |
| Cost of Goods Sold | $2.97B | $2.22B |
| Gross Profit | $5.18B | $10.50B |
| Research & Development | $1.49B | $2.73B |
| Operating Income (EBIT) | $1.18B | $5.41B |
| EBITDA | $4.08B | $5.92B |
| Pre-Tax Income | $1.97B | $3.46B |
| Income Tax | $243.00M | $696.80M |
| Net Income (Profit) | $1.73B | $2.76B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | AMGN | LLY |
|---|---|---|
| Cash & Equivalents | $8.81B | $3.09B |
| Total Current Assets | $26.93B | $41.26B |
| Total Current Liabilities | $23.01B | $30.07B |
| Long-Term Debt | $54.01B | $34.50B |
| Total Shareholders Equity | $6.21B | $15.85B |
| Retained Earnings | $-27.14B | $15.10B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | AMGN | LLY |
|---|---|---|
| Operating Cash Flow | $1.71B | $4.88B |
| Capital Expenditures | $-411.00M | $-1.51B |
| Free Cash Flow | $980.00M | $-1.60B |
| Debt Repayment | $-2.50B | N/A |
| Common Stock Repurchase | N/A | $-1.20B |
Short Interest & Institutional Ownership Analysis
| Metric | AMGN | LLY |
|---|---|---|
| Shares Short | 14.70M | 7.64M |
| Short Ratio | 5.46 | 2.48 |
| Short % of Float | 0.03% | 0.01% |
| Average Daily Volume (10 Day) | 1,887,960 | 3,814,363 |
| Average Daily Volume (90 Day) | 2,390,963 | 3,413,861 |
| Shares Outstanding | 537.00M | 897.54M |
| Float Shares | 536.32M | 895.49M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.84% | 0.84% |
Dividend Analysis & Yield Comparison: Amgen vs Eli Lilly and
| Metric | AMGN | LLY |
|---|---|---|
| Last 12-Month Dividend | $9.26 | $4.10 |
| Last 12-Month Dividend Yield | 3.20% | 0.52% |
| 3-Year Avg Annual Dividend | $8.72 | $4.02 |
| 3-Year Avg Dividend Yield | 0.79% | 0.22% |
| 3-Year Total Dividends | $26.16 | $12.05 |
| Ex-Dividend Date | May 16, 2025 | Feb 14, 2025 |